Skip to main content
Equibles
BIIB logo

BIIB · Biogen Inc. · Financials

Track BIIB — free

Use BIIB with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BIIB.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$243.10 +9.62 (+4.12%)
S&P 500 member Russell 1000 member Rebalance outlook locked
Market Cap
$35.75B
Shares
147.64M
Volume · Oct 20 1.49M Avg daily vol (3M) 1.01M

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Pull these statements through the financial statements API or MCP →
Revenue
$9.89B +2.2%
FY2025 Revenue FY2007–FY2025
Net Income
$1.29B -20.8%
FY2025 Net Income FY2007–FY2025
Gross Margin
86.57% +0.2pp
FY2020 Gross Margin FY2009–FY2020
Operating Margin
25.87% -8pp
FY2021 Operating Margin FY2007–FY2021
Diluted EPS
$8.79 -21.4%
FY2025 Diluted EPS FY2007–FY2025
Operating Cash Flow
$2.2B -23.3%
FY2025 Operating Cash Flow FY2007–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow Adjusted All Metrics
Annual Quarterly
Line Item FY2026 (G) TTM FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011 FY2010 FY2009 FY2008 FY2007
— $10.03B $9.89B $9.68B $9.84B $10.17BG $10.98BG $13.44BG $14.38B $13.45B $12.27B $11.45B $10.76B $9.7B $6.93B $5.52B $5.05B $4.72B $4.38B $4.1B $3.17B
— $2.61B $2.4B $2.31B $2.53B $2.28B $2.11B $1.81B $1.96B $1.82B $1.63B $1.48B $1.24B $1.17B $857.7M $545.49M $466.78M $400.26M $382.1M $401.99M $335.19M
— — — — — — — $11.64B $12.42B $11.64B $10.64B $9.97B $9.52B $8.53B $6.07B $4.97B $4.58B $4.32B $4B — —
— — — — — — — 86.57% 86.4% 86.5% 86.72% 87.08% 88.48% 87.93% 87.63% 90.11% 90.76% 91.51% 91.27% — —
— $2.01B $1.78B $1.98B $2.45B $2.23B $2.5B $3.99B $2.28B $2.6B $2.25B $1.97B $2.01B $1.89B $1.44B $1.33B $1.22B $1.25B $1.28B $1.07B $925.16M
— $2.59B $2.43B $2.4B $2.55B $2.4B $2.67B $2.5B $2.37B $2.11B $1.93B $1.95B $2.11B $2.23B $1.71B $1.28B $1.06B $1.03B $911.03M $925.31M $776.1M
— — $507.1M $386.5M $240.6M $246.3M $252M $255.1M $274M $381.2M $455.3M $373.4M $382.6M $489.8M $342.9M $202.2M $208.57M $208.93M $289.81M $332.75M $257.5M
— $842.9M $779.9M $673.2M $494.8M $518.4M $487.7M $457.2M $464.7M $650.5M $1.08B $682.7M $600.4M $688.1M $531.7M $365.65M $358.93M $355.74M $427.96M $462.06M $380.29M
— $187.3M $48.6M $30.2M $218.8M $131.1M $0 $0 $1.5M $12M $900K $33.1M $93.4M $0 $0 $2.23M $19.03M $75.15M — — —
— $9.02B $8.33B $7.77B $8.54B $6.58B $9.24B $8.4B $7.34B $7.56B $6.93B $6.3B $5.87B $5.75B $4.44B $3.71B $3.32B $3.47B $3.08B $2.88B $2.39B
— $2.48B — — — — $2.84B $4.55B $7.04B $5.89B $5.35B $5.15B $4.89B $3.97B $2.52B $1.86B $1.72B $1.25B $1.3B $1.21B $779.77M
— — — — — — 25.87% 33.84% 48.98% 43.77% 43.55% 45% 45.44% 40.94% 36.29% 33.64% 34.16% 26.48% 29.59% 29.62% 24.59%
— $3.01B — — — — $3.33B $5.01B $7.51B $6.54B $6.43B $5.83B $5.49B $4.66B $3.05B $2.22B $2.08B $1.6B $1.72B $1.68B $1.16B
— $284.8M $267.5M $250.3M $246.9M $246.6M $253.6M $222.5M $187.4M $200.6M $250.8M $260M $95.5M $29.5M $31.9M $36.5M $33M $36.1M $35.8M $52M —
— $132M $125M $67.6M $276.5M $89.3M $11M $42M $120M $112.5M $78.5M $63.4M $22.1M $12.2M $8.2M $29.5M $19.2M $22.3M $48.5M $72.1M —
— -$308.1M -$305.6M -$343.6M -$315.5M $108.2M -$1.1B $497.4M $83.3M $11M -$217M -$218.7M -$123.7M -$25.8M -$34.9M -$744K -$13.48M -$18.98M $37.25M -$57.73M $72.4M
— — — $0 $0 $2.6M $34.9M $3.3M -$77.4M $0 $0 $0 -$12.5M -$15.1M -$17.2M -$4.52M $0 $0 — — —
— — — — — — — — — — — — — — — — $15.06M $16.32M $23.97M -$1.08M -$16.73M
— $1.01B $1.56B $1.91B $1.3B $3.59B $1.75B $5.05B $7.13B $5.9B $5.13B $4.93B $4.77B $3.95B $2.48B $1.86B $1.71B $1.23B $1.33B $1.16B $852.17M
— $176.8M $263.6M $273.8M $135.3M $632.8M $52.5M $992.3M $1.16B $1.43B $2.46B $1.24B $1.16B $989.9M $601M $470.55M $444.53M $331.33M $355.62M $365.78M $272.42M
— $834.6M $1.29B $1.63B $1.16B $3.05B $1.56B $4B $5.89B $4.43B $2.54B $3.7B $3.55B $2.93B $1.86B $1.38B $1.23B $1.01B $970.13M $783.17M $638.17M
— — 13.07% 16.87% 11.81% 29.95% 14.17% 29.76% 40.96% 32.93% 20.69% 32.34% 32.95% 30.25% 26.86% 25.02% 24.45% 21.31% 22.16% 19.11% 20.12%
— — $0 $0 $400K -$85.3M $171.5M $59.9M $0 $43.3M $131M -$7.1M $46.2M $6.8M $0 $0 $32.26M -$106.7M $6.93M $6.94M -$58.43M
— — — — — — — — — — — — — — $1.86B $1.38B $1.23B $1B $968.4M $781.9M —
— $945M $1.25B $1.65B $1.17B $2.99B $1.75B $3.84B $5.99B $4.51B $2.54B $3.61B $3.38B $2.9B $1.89B $1.35B $1.23B $933.17M — — —
USD/shares — $5.68 $8.83 $11.21 $8.02 $20.96 $10.44 $24.86 $31.47 $21.63 $11.94 $16.96 $15.38 $12.42 $7.86 $5.80 $5.09 $3.98 $3.37 $2.67 $2.02
USD/shares $12.00 – $13.00* $5.63 $8.79G $11.18 $7.97G $20.87G $10.40G $24.80G $31.42 $21.58 $11.92 $16.93 $15.34 $12.37 $7.81 $5.76 $5.04 $3.94 $3.35 $2.65 $1.99
shares — — 146.5M 145.6M 144.7M 145.3M 149.1M 160.9M 187.1M 204.9M 212.6M 218.4M 230.7M 236.4M 236.9M 237.94M 242.4M 252.31M 287.36M 292.33M 315.84M
shares — — 147.1M 145.9M 145.6M 146M 149.6M 161.3M 187.4M 205.3M 213M 218.8M 231.2M 237.2M 238.3M 239.74M 245.03M 254.87M 289.48M 294.98M 320.17M
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2007–FY2024: $36.14B in buybacks.

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balanceAs ofAmountSource
Long-term debt, including current maturities 2026-06-30 USD 7,290,300,000 10-Q filed 2026-07-29
Related accounting measures — not additional borrowing

Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.

Current portion of secured debt
USD 800,000,000
Notes payable, including current maturities
USD 8,090,200,000
Noncurrent operating lease liabilities 2026-06-30 USD 264,800,000 10-Q filed 2026-07-29
2 filing observations remain unmatched and are excluded from instrument histories.
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
1 filing has incomplete source or extraction coverage. Verified observations are shown; missing observations do not establish that debt was unchanged.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
4.16×
Peer median 4.82×
EV/EBIT
—
P/E (TTM)
—
Peer median 27.03×

Peer medians compare against the 6 similar-size Drug Manufacturers - General companies (of 15 listed).

Valuation over time computed as of each quarter's filing date

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Segment (USD)

Component FY2025 FY2024 FY2023 FY2022
Reportable Segment $9,890,600,000 $9,675,900,000 $9,835,600,000 $10,173,400,000

By Geography (USD)

Component FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
United States $12,051,200,000 $10,982,400,000 $13,154,400,000 $16,273,700,000 $17,542,900,000 $23,559,000,000 $25,317,700,000 $25,161,100,000
Non Us $11,679,100,000 $13,221,200,000 $13,572,300,000 $15,129,800,000 $16,979,400,000 $14,867,200,000 $13,945,400,000 $12,387,300,000
Europe Excluding Germany — — $2,139,500,000 $2,424,900,000 $2,645,400,000 $2,503,400,000 $2,678,000,000 —
Segment Geographical Groups Of Countries Group Other — — $531,200,000 $646,900,000 $688,400,000 $619,300,000 $629,500,000 $511,400,000
Germany — — $868,000,000 $926,200,000 $1,162,400,000 $1,161,200,000 $1,126,400,000 —
Asia — — $863,400,000 $767,300,000 $761,400,000 $629,600,000 $432,500,000 $377,400,000
Europe — — — — — $3,664,600,000 $3,804,400,000 $3,403,200,000

By Product & Service (USD)

Component FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Product $7,119,400,000 $7,213,500,000 $7,246,700,000 $7,987,800,000 $8,846,900,000 $10,692,200,000 $11,379,800,000 $10,886,800,000
MS Product Revenues $4,038,900,000 $4,349,800,000 $4,661,900,000 $5,430,200,000 $6,096,700,000 $7,832,100,000 $8,529,300,000 $8,595,200,000
Rare Disease Product Revenue $2,154,200,000 $1,988,100,000 $1,803,000,000 $1,793,500,000 $1,905,100,000 — — —
Revenues from Anti-CD20 Therapeutic Programs $1,860,600,000 $1,749,900,000 $1,689,600,000 $1,700,500,000 $1,658,500,000 $1,977,800,000 $2,290,400,000 $1,980,200,000
Tysabri Product $1,665,400,000 $1,715,000,000 $1,876,900,000 $2,030,900,000 $2,063,100,000 $1,946,100,000 $1,892,200,000 $1,864,000,000
SPINRAZA $1,546,800,000 $1,573,200,000 $1,741,200,000 $1,793,500,000 $1,905,100,000 $2,052,100,000 $2,097,000,000 $1,724,200,000
Fumarate $1,426,500,000 $1,595,100,000 $1,588,800,000 $1,997,300,000 $2,362,300,000 $3,905,400,000 $4,438,200,000 $4,274,100,000
Royalty Attributed to OCREVUS $1,414,900,000 $1,339,500,000 $1,266,200,000 $1,136,300,000 $991,700,000 $845,400,000 — —
Interferon $945,600,000 $968,000,000 $1,105,700,000 $1,305,400,000 $1,566,100,000 $1,877,500,000 $2,101,800,000 $2,363,000,000
VUMERITY $746,800,000 $628,000,000 $576,300,000 $553,400,000 $410,400,000 $64,300,000 $5,500,000 $0
Contract Manufacturing Royalty and Other Revenue $732,900,000 $652,600,000 $899,300,000 $485,100,000 $476,300,000 $774,600,000 $707,700,000 $585,900,000
Biosimilars $729,100,000 $793,100,000 $770,000,000 $751,100,000 $831,100,000 $795,800,000 $738,300,000 $545,100,000
AVONEX $695,500,000 $707,500,000 $811,000,000 $973,500,000 $1,208,700,000 $1,491,900,000 — —
TECFIDERA $679,700,000 $967,100,000 $1,012,500,000 $1,443,900,000 $1,951,900,000 $3,841,100,000 $4,432,700,000 $4,274,100,000
Contract Manufacturing and Other Revenue $679,400,000 $592,100,000 $848,200,000 $417,700,000 $427,700,000 $719,100,000 $584,500,000 $459,400,000
SKYCLARYS $520,500,000 $382,500,000 $55,900,000 $0 $0 — — —
BENEPALI $453,200,000 $479,100,000 $438,800,000 $441,000,000 $498,300,000 $481,600,000 $486,200,000 $485,200,000
PLEGRIDY $250,100,000 $260,500,000 $294,700,000 $331,900,000 $357,400,000 $385,600,000 — —
Other $197,200,000 $82,500,000 $11,800,000 $13,000,000 $14,000,000 — — —
ZURZUVAE $195,100,000 $72,200,000 $1,600,000 $0 — — — —
IMRALDI $190,200,000 $213,100,000 $222,100,000 $224,500,000 $233,400,000 $216,300,000 $184,000,000 $16,700,000
Alzheimers Collaboration $177,700,000 $59,900,000 $0 $0 — — — —
QALSODY $86,900,000 $32,400,000 $5,900,000 $0 $0 — — —
Royalty $53,500,000 $60,500,000 $51,100,000 $67,400,000 $48,600,000 $55,500,000 $17,000,000 $38,700,000
FLIXABI $52,600,000 $63,200,000 $77,400,000 $81,300,000 $99,400,000 $97,900,000 $68,100,000 $43,200,000
BYOOVIZ $32,400,000 $36,600,000 $31,700,000 $4,300,000 $0 $0 — —
FUMADERM and ADUHELM $2,100,000 $10,300,000 $10,200,000 $13,000,000 — — — —
FAMPYRA $1,400,000 $71,700,000 $90,500,000 $96,600,000 $105,200,000 $103,100,000 $97,100,000 $92,700,000
TOFIDENCE $700,000 $1,100,000 $0 $0 — — — —
ADUHELM — — — $4,800,000 $3,000,000 $0 $0 —
ALPROLIX — — — — — — $0 $0
ELOCTATE — — — — — — $0 $0
FUMADERM — — — $8,200,000 $11,000,000 $12,200,000 $15,200,000 $22,300,000
Hemophilia Products — — — — — — $0 $0
ZINBRYTA — — — — — $0 $0 $1,400,000
Key facts CIK 875045 CUSIP 09062X103 13F (30d) 163 filings 148 filers Visit website Investor relations